GlassScriptPhysician profile
Brittany Marie Moates
NPI 1538658091
$5,820.57
in general payments reported to CMS, 2019-2025
23 companies · $875 in 2025
The $875 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $119 · 2021: $394 · 2022: $1,393 · 2023: $808 · 2024: $2,105 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,119.20 | 2020-2024 | |
| Harrow Eye, LLC | $648.84 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $511.06 | 2021-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Alcon Vision LLC | $472.38 | 2022-2025 | Rocklatan, Hydrus Microstent, Rhopressa |
| Tarsus Pharmaceuticals, INC. | $356.26 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $331.71 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $293.84 | 2022-2025 | Miebo, Xiidra |
| Dompe US, INC. | $267.74 | 2020-2025 | Oxervate |
| Abbvie INC. | $234.00 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $219.34 | 2020-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $174.70 | 2025 | |
| Amgen INC. | $165.96 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $163.83 | 2019-2021 | |
| Horizon Therapeutics Plc | $162.72 | 2022-2023 | Tepezza |
| Thea Pharma INC. | $162.56 | 2023-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $148.37 | 2020-2024 | Idose |
| Allergan, INC. | $132.62 | 2020-2022 | |
| Sight Sciences, INC. | $82.90 | 2022-2024 | Omni Surgical System |
| Coopervision INC. | $60.57 | 2025 | Myday Contact Lens |
| Rxsight INC | $49.40 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.76 | 2020 | |
| New World Medical,INC. | $21.25 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $19.56 | 2025 | Humphrey Hfa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Moates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.